Show simple item record

dc.contributor.authorCalifano, Raffaele
dc.contributor.authorGriffiths, Richard W
dc.contributor.authorLorigan, Paul C
dc.contributor.authorAshcroft, Linda
dc.contributor.authorTaylor, Paul
dc.contributor.authorBurt, Paul A
dc.contributor.authorLee, Lip W
dc.contributor.authorChittalia, Abbas
dc.contributor.authorHarris, Maggie A
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorThatcher, Nick
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2012-05-28T11:39:26Z
dc.date.available2012-05-28T11:39:26Z
dc.date.issued2011-09
dc.identifier.citationRandomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. 2011, 73 (3):338-44 Lung Canceren_GB
dc.identifier.issn1872-8332
dc.identifier.pmid21296449
dc.identifier.doi10.1016/j.lungcan.2011.01.001
dc.identifier.urihttp://hdl.handle.net/10541/226211
dc.description.abstractThe role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose.
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en_GB
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshAntineoplastic Protocols
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshDisease Progression
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMaximum Tolerated Dose
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshNeutropenia
dc.subject.meshQuality of Life
dc.subject.meshSurvival Analysis
dc.subject.meshTaxoids
dc.subject.meshThrombocytopenia
dc.subject.meshTreatment Outcome
dc.titleRandomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. raffaele.califano@christie.nhs.uken_GB
dc.identifier.journalLung Canceren_GB
html.description.abstractThe role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose.


Files in this item

This item appears in the following Collection(s)

Show simple item record